The University of Minnesota Masonic Cancer Center will use its grant mon to fund an exciting project exploring the use of genetically modified Natural Killer Cells (NKCs) as a groundbreaking immunotherapy for recurrent WHO grade 4 astrocytoma/glioblastoma (G4A/GBM). By using the FT536 NKC line, this project aims to usher in a new era of brain cancer treatment.
The project has a dual focus:
- Translational research to understand the biological changes needed to optimize NKC therapy.
- A first-of-its-kind phase 1 clinical trial designed to test the safety and effectiveness of FT536 through surgical biopsies, direct brain injections, and intraventricular administration. With rigorous patient monitoring throughout, this trial aims to provide vital insights into new treatments for brain cancer patients.
- With brain cancer treatment desperately in need of innovation, this project underscores the urgency for new therapies. The funds will primarily cover clinical trial costs (80%), with the remaining support directed toward laboratory research. Thanks to Fate Therapeutics’ commitment to provide FT536 at no cost, this initiative is poised to enroll its first patients by Spring 2025, pending funding and institutional approvals. This project perfectly aligns with the mission of Humor to Fight the Tumor, offering a chance to pioneer life-saving treatments and improve the lives of brain cancer patients.